Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: metformin, exenatide or combined (metformin & exenatide ) Clear all
Completed No phase listed Observational

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

NCT00806520
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 9, 2026, 4:55 PM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

NCT00717457
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
exenatide, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Haleyville, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 9, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin

NCT00753896
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Mesa, Arizona • Tempe, Arizona • Concord, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Oct 9, 2026, 4:55 PM EDT
Completed Phase 4 Interventional Results available

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)

NCT01524705
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin Glargine, Metformin, Prandial insulin, Exenatide
Drug
Lead sponsor
University of Washington
Other
Eligibility
40 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 9, 2026, 4:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

NCT00894322
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 9, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 9, 2026, 4:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Exenatide and Metformin Therapy in Overweight Women With PCOS

NCT00344851
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
metformin, exenatide or combined (metformin & exenatide )
Drug
Lead sponsor
Metabolic Center of Louisiana Research Foundation
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 11, 2007 · Synced Oct 9, 2026, 4:55 PM EDT
Not listed Phase 4 Interventional

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

NCT04027023
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes mellitus Type 2 De-escalation treatment (DET)
Drug
Lead sponsor
Sciema UG
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 9, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

NCT00641056
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide Once Weekly, Insulin Glargine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Escondido, California • Jacksonville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2015 · Synced Oct 9, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

NCT02635386
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obesity
Interventions
Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA, Dapagliflozin plus Glucophage (MET ER), Phentermine /Topiramate (PHEN/ TPM) ER
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 9, 2026, 4:55 PM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00518882
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 9, 2026, 4:55 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Liver and Fat Regulation in Overweight Adolescent Girls

NCT02157974
View directory record Official record
Conditions
Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
Interventions
Byetta 5Mcg Pen Injection
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 9, 2026, 4:55 PM EDT